Asyst Therapeutics
Pioneering the Future of Polycystic Kidney Disease Treatment
Targeting the root cause of cyst formation with next-generation therapeutics.
At Asyst Therapeutics, we are dedicated to developing transformative therapies for polycystic kidney and liver disease (ADPKD). Our innovative approach directly targets and eliminates cyst-lining cells, addressing the root cause of cyst formation and disease progression. Founded by Dr. Sorin Fedeles and Dr. Matteus Krappitz, our company builds upon groundbreaking research from Yale University to improve treatment options for patients worldwide.
Why Asyst Therapeutics?
✔ Next-Generation Therapeutics – Designed to modify disease progression by targeting cyst-lining cells.
✔ Targeted Approach – Focused on eliminating cyst-lining cells.
✔ Leading Experts – Founded by specialists in nephrology, genetics and biomedical research.
Join the Future of PKD Treatment
Contact Us Today!
Get In Touch
📨 Email: matteus.krappitz@asystx.com
& sorin.fedeles@asystx.com
At Asyst Therapeutics, we’re dedicated to developing breakthrough treatments for polycystic kidney and liver disease (ADPKD/ADPLD). Whether you’re a researcher, clinician, patient advocate, or industry partner, we welcome collaboration.
Take the First Step Toward Innovation. Contact Us Today.